Cancer/Tumor Profiling Market Report | the Demand for the Market Will Drastically Increase in the Future
Cancer/tumor profiling gives information on the genes that cause cancer, which can help researchers better understand how cancer works. Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling has become increasingly important in molecular diagnosis, since a better understanding of cancer tumours aids physicians in making appropriate therapeutic decisions and avoiding “over-treatment” of cancer patients.
Oncologists' increasing demand for cancer profiling methods to diagnose or treat malignancies, as well as forecast response to targeted therapy, is driving the Cancer/Tumor Profiling Market. Furthermore, an increase in the use of cancer biomarkers for tumour profiling, an increase in cancer incidence around the world, and an increase in the use of next-generation sequencing techniques for cancer profiling all contribute to the market's growth. However, the market's expansion is hampered by expensive monetary investments in biomarker research and a scarcity of experienced specialists or oncologists that specialise in tumour profiling.
The Cancer/Tumor Profiling Market is expected to grow at a rapid rate in the coming years, owing to increased funding directed toward activities aimed at improving the overall course of disease diagnosis and treatment, as well as significant technological advancements recently observed in the field of tumor profiling. The growing use of point-of-care diagnostics, as well as the demand for tailored medicines, are driving the Cancer/Tumor Profiling Market.
Over 60 percent of new cancer cases are anticipated to occur in Asia, Africa, and South and Central America, and 70 percent of cancer fatalities are also estimated to occur in these regions. These regions could be the key contributors to worldwide cancer/tumor profiling market's growth and development, owing to a large patient pool and potential consumers. The market is now led by developed regions with high disposable incomes, such as North America and Europe. Apart from the growing number of cancer patients in these areas, the market for cancer/tumor profiling is booming thanks to technologically enhanced healthcare infrastructures, advanced research and development facilities, and a plethora of technology providers.
Proteome Sciences PLC, Life Technologies Corporation, Illumina, Inc., BioTheranostics, RiboMed Biotechnologies Inc., NeoGenomics Laboratories, Oxford Gene Technology Ltd., Genomic Health Inc., Agendia, and Oncopath Laboratories are some of the major key players in the Cancer/Tumor Profiling Market.
Comments
Post a Comment